Autres langues CASI Pharmaceuticals, Inc.

Actions

CASI

KYG1933S1012

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 03/05/2024			Varia. 5j.	Varia. 1 janv.
2,795 ^USD	+4,29 %		+15,50 %	-60,96 %

28/03	CASI Pharmaceuticals, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI
05/03	Les plus fortes hausses de la mi-journée	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS	08/04
CASI Pharmaceuticals : Received Emergency Relief in connection with the Dispute with Juventas - Form 6-K	08/04
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS	28/03
CASI Pharmaceuticals : Received Notice of Termination of Commercialization Collaboration for CNCT19 from Juventas - Form 6-K	13/03
BioInvent International, CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed, Refractory Indolent Non-Hodgkin's Lymphoma In China	06/03
Top Midday Gainers	05/03
Looming Employment Report, Powell Testimony Stifle US Equity Futures Pre-Bell	05/03
Rate Cut Uncertainty Pushes Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday	05/03
Top Premarket Gainers	05/03
BioInvent International: CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma In China	05/03
CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China	05/03
CASI Pharmaceuticals Report Positive Interim Phase 1 Data for BI-1206 in the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma in China	05/03
CASI Pharmaceuticals, Inc. and CASI Pharmaceuticals Co. Ltd Enter into Certain Agreement with Respect to the Renewal of the Exclusive Distribution Agreement with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd	29/02
CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA	16/02
Casi Pharmaceuticals Announces First Dose of Folotyn in China	16/02
CASI Pharmaceuticals, Inc. Announces Resignation of Fuqiang Zhang as Chief Commercial Officer	12/02
CASI Pharmaceuticals, Inc. Appoints of Mr. Huang Hai as the Global Chief Commercial Officer	30/01
CASI Pharmaceuticals : Enters into Certain Agreements with respect to CASI Wuxi’s Reduction in Registered Capital and Convertible Loan - Form 6-K	15/12
CASI Pharmaceuticals : Enters into an Exclusive Distribution Agreement - Form 6-K	08/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues CASI Pharmaceuticals, Inc.

Actions

CASI

KYG1933S1012

Autres langues

Filtres